Trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Trial in Healthy Adults to Evaluate the Safety, Tolerability, and PK of MK-7762

Study Director
Charles Wells
Start Date
2 / 2023
Trial Phase
Phase I
Trial Status
enrolling
Current Enrollment
Target Enrollment
96
Overview
Registry Link
Developer Associations
Bill & Melinda Gates Medical Research Institute
Compound Associations
TBD09 (MK7762)